{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:17:36Z","timestamp":1791137856962,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3537,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.exphem.2012.05.013","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T06:17:34Z","timestamp":1338877054000},"page":"811-819.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Peroxisome proliferator\u2013activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"40","author":[{"given":"Lihui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Giannoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2012.05.013_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.exphem.2012.05.013_bib2","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.013_bib3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.exphem.2012.05.013_bib4","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.013_bib5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1124\/jpet.105.099929","article-title":"The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha","volume":"317","author":"Saborowski","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2012.05.013_bib6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2133\/dmpk.21.437","article-title":"Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems","volume":"21","author":"Nakata","year":"2006","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.exphem.2012.05.013_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/nar\/26.2.497","article-title":"An alternative splice variant of the tissue specific transcription factor HNF4alpha predominates in undifferentiated murine cell types","volume":"26","author":"Nakhei","year":"1998","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2012.05.013_bib8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2337\/diab.46.3.386","article-title":"Mapping novel pancreatic islet genes to human chromosomes","volume":"46","author":"Ferrer","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.exphem.2012.05.013_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI0215085","article-title":"Genetic evidence that HNF-1alpha-dependent transcriptional control of HNF-4alpha is essential for human pancreatic beta cell function","volume":"110","author":"Hansen","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2012.05.013_bib10","doi-asserted-by":"crossref","first-page":"G207","DOI":"10.1152\/ajpgi.00057.2004","article-title":"Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha and -gamma","volume":"288","author":"Nie","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.exphem.2012.05.013_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0165-6147(00)01559-5","article-title":"PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer","volume":"21","author":"Murphy","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.exphem.2012.05.013_bib12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.bbrc.2006.09.099","article-title":"PPARalpha agonists up-regulate organic cation transporters in rat liver cells","volume":"350","author":"Luci","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2012.05.013_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.105.093765","article-title":"Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha","volume":"317","author":"Moffit","year":"2006","journal-title":"J.Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2012.05.013_bib14","doi-asserted-by":"crossref","first-page":"23812","DOI":"10.1074\/jbc.M604890200","article-title":"Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells","volume":"281","author":"Szatmari","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2012.05.013_bib15","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.013_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2141.2002.03705.x","article-title":"Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia","volume":"118","author":"Wang","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.05.013_bib17","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.013_bib18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/31701","article-title":"Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators","volume":"393","author":"Staels","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2012.05.013_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1476-5381.2009.00208.x","article-title":"Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs","volume":"157","author":"Schinner","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.exphem.2012.05.013_bib20","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2012.05.013_bib21","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.013_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in\u00a0vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.013_bib23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","article-title":"Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity","volume":"24","author":"Engler","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.013_bib24","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.4161\/cc.5.19.3259","article-title":"Dual PPARalpha\/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines","volume":"5","author":"Zang","year":"2006","journal-title":"Cell Cycle"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12002196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12002196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:29:56Z","timestamp":1759566596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X12002196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0301472X12002196"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2012.05.013","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peroxisome proliferator\u2013activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2012.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}